Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO6874281 plus atezolizumab in advanced or metastatic solid tumors
2017-003182-94Phase 2Unknown
- Sponsor
- Roche
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of simlukafusp alfa and atezolizumab in Nonhematologic neoplasms (4 arms), sponsored by Roche. Primary endpoint: Objective response rate. Status: unknown.
02
Drugs
simlukafusp alfaatezolizumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2017-003182-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003182-94.